uniQure (NASDAQ:QURE) Shares Gap Up - What's Next?

uniQure (NASDAQ:QURE - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $15.04, but opened at $15.90. uniQure shares last traded at $15.29, with a volume of 103,586 shares traded.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wells Fargo & Company dropped their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. Guggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Chardan Capital restated a "buy" rating and issued a $38.00 target price on shares of uniQure in a research note on Friday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of uniQure in a report on Thursday. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, uniQure has an average rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Stock Down 2.3%

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $797.54 million, a PE ratio of -2.94 and a beta of 0.10. The business's 50 day simple moving average is $12.53 and its 200 day simple moving average is $12.87.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. As a group, analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. The trade was a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares of the company's stock, valued at approximately $2,240,441.70. The trade was a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,129 shares of company stock valued at $412,927 in the last ninety days. 4.74% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC bought a new position in shares of uniQure during the 4th quarter valued at about $38,410,000. Vestal Point Capital LP boosted its stake in shares of uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after buying an additional 1,767,572 shares during the last quarter. RTW Investments LP boosted its stake in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after buying an additional 893,625 shares during the last quarter. Point72 Asset Management L.P. lifted its position in uniQure by 81.3% during the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new position in uniQure during the fourth quarter valued at $13,245,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.